pancreatic%20cancer
PANCREATIC CANCER
Pancreatic cancer is malignancy arising from the pancreas.
It is the 13th most common cancer in the world, 10th most common in the United States, and 4th leading cause of cancer-related deaths in the United Stated and Europe.
Exocrine tumors account for 95% of malignant pancreatic disease.
It is more common in women.
The median age of occurrence is at 71 years old.

Signs and Symptoms

  • Jaundice
    • Common in patients w/ malignancy in the head of the pancreas
  • Abdominal pain
    • Common in patients w/ tumors located in the body and tail of the pancreas
  • Weight loss
  • Back pain
  • Symptoms secondary to compression caused by the tumor:
    • Nausea/vomiting
    • Anorexia
    • Dyspepsia
    • Gastrointestinal bleeding
  • Symptoms caused by biliary obstruction:
    • Dark urine
    • Lightly colored-grayish stool
    • Pruritus
    • Infections (cholangitis, pancreatitis)
    • Scleral icterus
  • Symptoms caused by pancreatic enzyme insufficiency:
    • Malabsorption
    • Fatty stools
    • Increased flatulence
    • Ascites

Risk Factors

High Risk:
  • Familial atypical multiple-mole melanoma (FAMMM)
  • Hereditary pancreatitis
  • Peutz-Jeghers syndrome
  • >3 1st-degree relatives diagnosed w/ pancreatic cancer
Moderate Risk:
  • 2 1st-degree relatives diagnosed w/ pancreatic cancer
  • Cystic fibrosis
  • Chronic pancreatitis
  • BRCA2 mutation carrier
  • PALB2 mutation carrier
Low Risk:
  • Cigarette smoking
  • Diabetes mellitus (DM)
  • Obesity/Increased body mass index (BMI)
  • Occupational exposure to chemicals (eg beta-naphthylamine, benzidine)
  • Heavy alcohol consumption
  • One 1st-degree relative diagnosed w/ pancreatic cancer
  • Increased consumption of red/processed meat and dairy products
  • Low intake of fruits & vegetables
  • Low plasma 25-hydroxyvitamin D levels
  • History of gallstones & H. pylori infection
  • BRCA1 mutation carrier
  • Familial adenomatous polyposis
  • Li-Fraumeni syndrome
  • Lynch syndrome
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.